Lonza shares rose in early trading on Friday, gaining 1.0 percent to 647.00 Swiss francs. The broader Swiss Market Index increased by 0.25 percent. Since the beginning of the year, the pharmaceutical contract manufacturer's stock has risen by 20 percent. Despite this performance and the Swiss Market Index trading at a record high, Lonza shares remain roughly 25 percent below the all-time high of 784.50 francs reached five years ago. According to Barclays, the stock is expected to approach that level over the next twelve months.
Barclays reaffirmed its confidence in the company by lifting its price target from 730 to 770 francs while keeping the Overweight rating unchanged. In a note to clients, Barclays analyst Charles Pitman-King pointed to the company's recently stated medium-term targets as the driver for forecast adjustments. For the period spanning from 2026 to 2032, the analyst identifies additional earnings before interest, taxes, depreciation, and amortization potential in the low-to-high single-digit percentage range. Long-term prospects are viewed with high optimism, with Pitman-King projecting robust annual revenue growth of 11 percent over a decade from 2026 to 2036, alongside enhanced efficiency in converting earnings into free cash flow.
Bernstein SG also revised expectations upward a week prior, increasing its price target for Lonza shares from 835 to 887 francs while keeping an Outperform rating. In a client note, analyst Justin Smith highlighted significantly improved visibility on margin development following the recent capital markets day. His revised profit estimates stand clearly above the market consensus, driven by increased profitability within the biologics business supported by the Vacaville facility in the United States, where integration is progressing well. Additional momentum is expected from the divestment of the consumer division, which provides flexibility for strategic mergers and acquisitions through the first tranche of proceeds. According to AWP Analyzer, 18 analysts rate the stock as a buy alongside recommendations to hold, with an average price target of 700 francs.
Following its transformation into a focused pharmaceutical supplier, Lonza aims for higher profitability. In mid-October, ahead of an investor day, the Basel-based company presented financial targets indicating that core operating profit should outpace revenue growth. The company targets average organic revenue growth of 10 to 13 percent at constant exchange rates over the medium term, alongside an operating profit margin reaching the high 30 percent range. For 2026, Lonza anticipates a margin of 33 to 34 percent on local currency revenue growth of 11 to 12 percent. The growth commitment maintains previous elements of low-double-digit organic revenue expansion while introducing specific ambitions for return on invested capital and cash flow generation.
Lonza explicitly integrated return on invested capital and further cash flow improvements into its medium-term financial model. Return on invested capital is targeted to reach two to three times the weighted average cost of capital, while capital expenditure is projected to remain in the mid-to-high teens percentage range of revenue. Higher margins and return on invested capital aim to increase value creation per invested franc, with shareholder returns supported by an annually stable or rising dividend per share alongside selective share buybacks, as reported by the news agency AWP.
